120 related articles for article (PubMed ID: 11358673)
1. Pharmacokinetics and metabolism of formestane in breast cancer patients.
Lønning PE; Geisler J; Johannessen DC; Gschwind HP; Waldmeier F; Schneider W; Galli B; Winkler T; Blum W; Kriemler HP; Miller WR; Faigle JW
J Steroid Biochem Mol Biol; 2001 Apr; 77(1):39-47. PubMed ID: 11358673
[TBL] [Abstract][Full Text] [Related]
2. Metabolic studies of formestane in horses.
Leung GN; Kwok WH; Wan TS; Lam KK; Schiff PJ
Drug Test Anal; 2013 Jun; 5(6):412-9. PubMed ID: 23339113
[TBL] [Abstract][Full Text] [Related]
3. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
[TBL] [Abstract][Full Text] [Related]
4. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
[TBL] [Abstract][Full Text] [Related]
5. Formestane: an effective first-line endocrine treatment for advanced breast cancer.
Zilembo N; Bajetta E; Noberasco C; Buzzoni R; Vicario G; Bono A; Laffranchi A; Biasi G; Dolci S; Bichisao E
J Cancer Res Clin Oncol; 1995; 121(6):378-82. PubMed ID: 7797604
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Lønning PE
Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
[TBL] [Abstract][Full Text] [Related]
7. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
Jones AL; MacNeill F; Jacobs S; Lonning PE; Dowsett M; Powles TJ
Eur J Cancer; 1992; 28A(10):1712-6. PubMed ID: 1389491
[TBL] [Abstract][Full Text] [Related]
8. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
Wiseman LR; McTavish D
Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and bioconversions of formestane.
Martin GD; Narvaez J; Marti A
J Nat Prod; 2013 Oct; 76(10):1966-9. PubMed ID: 24074257
[TBL] [Abstract][Full Text] [Related]
10. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.
Dowsett M; Mehta A; King N; Smith IE; Powles TJ; Stein RC; Coombes RC
Eur J Cancer; 1992; 28(2-3):415-20. PubMed ID: 1591054
[TBL] [Abstract][Full Text] [Related]
11. Formestane in the treatment of advanced postmenopausal breast cancer.
Possinger K; Jonat W; Höffken K
Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
[TBL] [Abstract][Full Text] [Related]
12. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Wiseman LR; Goa KL
Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites.
Kohler M; Parr MK; Opfermann G; Thevis M; Schlörer N; Marner FJ; Schänzer W
Steroids; 2007 Mar; 72(3):278-86. PubMed ID: 17207827
[TBL] [Abstract][Full Text] [Related]
14. Role of human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C3) in the extrahepatic metabolism of the steroidal aromatase inactivator Formestane.
Wan R; Kong X; Yang Y; Tao S; Chen Y; Teichmann AT; Wieland FH
J Steroid Biochem Mol Biol; 2020 Apr; 198():105527. PubMed ID: 31733346
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
[TBL] [Abstract][Full Text] [Related]
16. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced breast cancer with formestane.
Murray R; Pitt P
Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
[TBL] [Abstract][Full Text] [Related]
18. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
[TBL] [Abstract][Full Text] [Related]
19. Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Di Leo A; Bartoli C; Merson M; Sacchini V; Moglia D; Celio L
Br J Cancer; 1994 Jul; 70(1):145-50. PubMed ID: 8018527
[TBL] [Abstract][Full Text] [Related]
20. Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
Nisslein T; Freudenstein J
Planta Med; 2007 Apr; 73(4):318-22. PubMed ID: 17354167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]